NEOG Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Neogen Corporation 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$11.78 |
| 52週高値 | US$12.85 |
| 52週安値 | US$4.90 |
| ベータ | 1.76 |
| 1ヶ月の変化 | 2.79% |
| 3ヶ月変化 | 29.45% |
| 1年変化 | 114.18% |
| 3年間の変化 | -43.26% |
| 5年間の変化 | -71.53% |
| IPOからの変化 | 4,509.49% |
最新ニュース
ナラティブ更新 • Sep 03
NEOG: 2027 Revenue Outlook And Screwworm Response Will Drive Bullish Case
Analysts have raised their price target on Neogen from $13 to $14, citing updated assumptions for revenue growth, profit margins, a slightly lower discount rate, and a revised future P/E expectation. What’s in the News for Neogen Neogen issued earnings guidance for the first quarter of fiscal 2027, with expected revenue in a range of $207 million to $209 million.
ナラティブ更新 • Aug 15
NEOG: Transformation Plan And Higher R&D Spending Will Shape Balanced Outlook
Analysts have raised their price target for Neogen to $12.00 from $11, citing modest adjustments to fair value estimates, a slightly lower discount rate, a smaller expected revenue decline, a stable profit margin outlook, and a marginally higher assumed future P/E multiple. What’s in the News for Neogen Neogen reported fiscal Q4 2026 revenue of US$225.3 million and a net loss of US$11.3 million, with core revenue growth of 4.3%, mainly from the Food Safety segment.Recent updates
ナラティブ更新 • Sep 03
NEOG: 2027 Revenue Outlook And Screwworm Response Will Drive Bullish Case
Analysts have raised their price target on Neogen from $13 to $14, citing updated assumptions for revenue growth, profit margins, a slightly lower discount rate, and a revised future P/E expectation. What’s in the News for Neogen Neogen issued earnings guidance for the first quarter of fiscal 2027, with expected revenue in a range of $207 million to $209 million.ナラティブ更新 • Aug 15
NEOG: Transformation Plan And Higher R&D Spending Will Shape Balanced Outlook
Analysts have raised their price target for Neogen to $12.00 from $11, citing modest adjustments to fair value estimates, a slightly lower discount rate, a smaller expected revenue decline, a stable profit margin outlook, and a marginally higher assumed future P/E multiple. What’s in the News for Neogen Neogen reported fiscal Q4 2026 revenue of US$225.3 million and a net loss of US$11.3 million, with core revenue growth of 4.3%, mainly from the Food Safety segment.
ナラティブ更新 • Aug 01
NEOG: 2027 Guidance And Margin Outlook Will Frame Balanced Return Potential
Analysts have raised their fair value estimate for Neogen from $12 to $13, citing updated assumptions around a lower discount rate, a projected shift to positive revenue growth, a slightly lower profit margin, and a higher future P/E multiple. What's in the News for Neogen Neogen issued earnings guidance for the first quarter of fiscal 2027, with expected revenue in a range of $207 million to $209 million.Seeking Alpha • Jun 27
Neogen: Still A Difficult Story
Summary Neogen has addressed urgent deleveraging needs through divestments and cost-cutting, but earnings power remains modest, and recent divestments were at low sales multiples. Q3 results were mixed: core food safety sales grew 4%, the animal segment fell 8% due to a supplier issue, and adjusted EBITDA margin rose to 22.8%. The $160M genomics business sale to Zoetis reduces net debt below $500M but was completed at only 1.5x sales, reflecting lagging margins and limited immediate value creation. Pro forma sales are now ~$800M, with realistic earnings estimates of $0.30-$0.45/share; organic growth and margin improvement remain critical for re-rating. Read the full article on Seeking Alphaナラティブ更新 • Jun 23
NEOG: Screwworm Response And Buybacks Will Support Bullish 2026 Outlook
Analysts have modestly revised their Neogen price target to $13.00, reflecting updated assumptions around a slightly lower discount rate, softer revenue growth expectations, reduced profit margins, and a higher future P/E multiple in their valuation models. What's in the News for Neogen Neogen expanded FIFRA Section 2(ee) recommendations for its Prozap Insectrin X Concentrate and Prozap Screw Worm and Ear Tick Aerosol products to support New World Screwworm response efforts in livestock, with approvals in Texas and availability in Florida.ナラティブ更新 • Jun 08
NEOG: Food Safety Execution And Manufacturing Shift Will Support Future Upside
Analysts have raised their price target on Neogen to $11.00. This reflects updated assumptions that include a slightly lower discount rate, a smaller expected decline in revenue growth, a marginally higher profit margin, and a modestly reduced future P/E multiple.ナラティブ更新 • May 25
NEOG: Raised 2026 Revenue Guidance And Higher P/E Expectation Will Support Upside
Analysts have raised their price target for Neogen to $11.00 from $10.00, citing updated assumptions around discount rates, revenue trends, profit margins, and a higher expected future P/E multiple. What's in the News Neogen issued updated guidance for fiscal 2026, focusing on its outlook for full year revenue (Key Developments).ナラティブ更新 • Apr 30
NEOG: Updated 2026 Revenue Outlook Will Support Future Upside Potential
Analysts have nudged their price target on Neogen slightly higher to $12, reflecting updated assumptions around discount rate, profit margin and future P/E that keep fair value broadly in line with prior estimates. What's in the News Neogen updated full fiscal year 2026 guidance, with projected revenue now in a range of $857 million to $860 million.ナラティブ更新 • Apr 15
NEOG: Recall Response And Updated 2026 Guidance Will Support Future Upside
Analysts have raised their price target on Neogen from $11.67 to $12.00, citing updated assumptions around discount rates, revenue trends, profit margins, and a higher future P/E of 32.21 compared with 28.61 previously. What's in the News Neogen updated full fiscal year 2026 guidance, indicating expected revenue in a range of $857 million to $860 million, compared with prior guidance of $845 million to $855 million (corporate guidance).ナラティブ更新 • Apr 01
NEOG: Earnings Outlook Will Benefit From Recall Actions And New Guidance
Analysts have raised their price target on Neogen from $8.17 to $11.67 per share, citing updated assumptions related to the discount rate, revenue growth, profit margins, and a higher future P/E multiple. What's in the News Neogen is voluntarily recalling all lots within expiry of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level due to microbial contamination identified in certain 10 mL / 50 mg vials.ナラティブ更新 • Mar 18
NEOG: Recall Resolution Will Shape Bullish View On 2026 Revenue Outlook
Analysts have kept Neogen's price target steady at $13.00, indicating only minor adjustments in assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock's valuation. What's in the News Neogen is voluntarily recalling all lots of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level due to microbial contamination identified in certain 10 mL / 50 mg vials, and is extending the recall to 2 mL / 20 mg vials while its investigation continues (Key Developments).ナラティブ更新 • Mar 04
NEOG: 2026 Outlook Will Rely On Recall Resolution For Upside
Analysts are holding Neogen's fair value estimate at $13.00 while modestly adjusting their assumptions around the discount rate, long term revenue trends, profit margins, and future P/E. This reflects updated views on the company’s risk profile and earnings potential without changing the overall price target level.ナラティブ更新 • Feb 18
NEOG: 2026 Revenue Outlook Will Support Continued Bullish Thesis
Analysts have maintained Neogen's price target at $13.00, noting that only minor adjustments to assumptions around discount rate, revenue growth, profit margins, and future P/E were made, which do not materially change their valuation view. What's in the News Neogen is voluntarily recalling all lots of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level, after microbial contamination was identified in certain 10 mL/50 mg vials used via intraarticular injection, which is inconsistent with the product's labeled use (Key Developments).ナラティブ更新 • Feb 03
NEOG: Higher Forward P/E And 2026 Outlook Will Support Bullish Thesis
Analysts have raised their price target on Neogen by an implied $3 per share, pointing to adjustments in fair value, discount rate, revenue growth expectations, profit margin assumptions, and a higher forward P/E multiple as the key drivers behind the change. What's in the News Neogen is voluntarily recalling all lots within expiry of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level due to microbial contamination identified in certain 10 mL/50 mg vials, with an expanded recall to 2 mL/20 mg vials while the investigation continues (Key Developments).分析記事 • Feb 02
Improved Revenues Required Before Neogen Corporation (NASDAQ:NEOG) Stock's 46% Jump Looks Justified
Despite an already strong run, Neogen Corporation ( NASDAQ:NEOG ) shares have been powering on, with a gain of 46% in...ナラティブ更新 • Jan 20
NEOG: Future CFO Transition And 2026 Guidance Will Support Measured Outlook
Analysts have raised their fair value estimate for Neogen from US$6.50 to US$10.00, reflecting updated assumptions regarding discount rates, revenue trends, profit margins and a higher future P/E multiple. What's in the News Neogen issued earnings guidance for fiscal 2026, with revenue anticipated in the range of US$845 million to US$855 million, giving investors a sense of management’s current expectations for the business (Key Developments).ナラティブ更新 • Jan 05
NEOG: New CFO Appointment Will Support Confidence In Earnings Outlook
Analysts now place a higher implied value on Neogen, lifting their fair value estimate from US$8.00 to US$10.00, citing updated assumptions around discount rates, revenue trends, profit margins, and a richer future P/E multiple. What's in the News Neogen appointed Bryan Riggsbee as Chief Financial Officer, effective November 3, 2025.分析記事 • Dec 19
Neogen Corporation (NASDAQ:NEOG) Shares Fly 34% But Investors Aren't Buying For Growth
The Neogen Corporation ( NASDAQ:NEOG ) share price has done very well over the last month, posting an excellent gain of...ナラティブ更新 • Dec 17
NEOG: Future CFO Transition And Guidance Stability Will Support Measured Outlook
Analysts have raised their price target on Neogen from approximately $5.00 to $6.50 per share, citing a slightly lower discount rate, modestly improved revenue trajectory, better profit margin expectations, and a willingness to assign a higher future P/E multiple. What's in the News Neogen appointed Bryan Riggsbee as Chief Financial Officer effective November 3, 2025, with outgoing CFO David Naemura supporting the transition through year end.ナラティブ更新 • Dec 03
NEOG: CFO Transition And Alliance Renewal Will Support Future Earnings
Analysts have modestly raised their price target on Neogen by about $0.20 per share, citing a slightly higher assumed discount rate and marginally richer future valuation multiples that together offset minor tweaks to long term growth and margin expectations. What's in the News Reaffirmed fiscal 2026 earnings guidance, maintaining full-year revenue expectations of $820 million to $840 million (company guidance).ナラティブ更新 • Nov 19
NEOG: Profit Margin Expansion And CFO Transition Will Drive Earnings Potential
Analysts have raised their price target for Neogen modestly, citing improved profit margin projections and a slightly lower expected future price-to-earnings ratio as key factors behind the adjustment. What's in the News Neogen appointed Bryan Riggsbee as its new Chief Financial Officer, effective November 3, 2025.ナラティブ更新 • Oct 31
NEOG: Rising Profit Margins And New Partnerships Will Drive Future Expansion
Narrative Update: Neogen Analyst Price Target Revised Analysts have slightly raised their price target for Neogen, citing improvements in expected profit margins and a modest decline in projected future valuation multiples. This has resulted in a new estimated fair value of $8.17 per share.ナラティブ更新 • Oct 17
Food Safety Testing Advances Will Expand Global Opportunities
Neogen's analyst target price has risen from $7.67 to $8.17, as analysts point to improved revenue growth projections alongside a reduced discount rate, both supporting a higher valuation. What's in the News Neogen introduced Molecular Detection Assay: Listeria Right Now, a rapid, enrichment-free tool for detecting Listeria species with results in about two hours and streamlined workflow benefits (Product-Related Announcements).ナラティブ更新 • Oct 03
Food Safety Testing Advances Will Expand Global Opportunities
Analysts have raised their price target for Neogen from $6.50 to $7.67, citing a slightly lower discount rate and forward profit expectations. Revenue growth projections remain stable.分析記事 • Jul 10
Is Neogen (NASDAQ:NEOG) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...新しいナラティブ • May 27
Food Safety And Genomics Will Expand Global Markets
Resilient core businesses, strategic divestitures, and efficiency initiatives are expected to stabilize revenue and expand margins as macro and operational conditions improve.分析記事 • May 16
Improved Revenues Required Before Neogen Corporation (NASDAQ:NEOG) Stock's 33% Jump Looks Justified
Those holding Neogen Corporation ( NASDAQ:NEOG ) shares would be relieved that the share price has rebounded 33% in the...Seeking Alpha • Apr 23
Neogen: A Fair Divestment (Rating Upgrade)
Summary Neogen's merger with 3M Food Safety led to significant debt and operational struggles, causing shares to plummet and the CEO to be ousted. Following disappointing sales and earnings, the company is exploring asset sales and restructuring, offering potential upside if stabilization occurs. Neogen's current valuation appears modest relative to sales, presenting a speculative opportunity for investors willing to take on risk. I am cautiously optimistic about Neogen's future, considering the potential for above-average returns if divestments are executed at reasonable valuations. Read the full article on Seeking Alpha分析記事 • Apr 11
Here's Why Neogen (NASDAQ:NEOG) Is Weighed Down By Its Debt Load
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Jan 14
Neogen: Food Safety Play Is Far From A Safe Pay
Summary Neogen Corporation's merger with 3M Food Safety in 2022 led to significant challenges, including valuation compression, debt increase, and underperformance, causing shares to plummet. Neogen's financial performance has been disappointing, with sales and EBITDA falling short of expectations and net debt increasing. The company's guidance for 2025 remains modest, and recent results have shown minimal revenue growth and high leverage ratios, frustrating investors. Trading at $12, NEOG's future hinges on management's ability to execute and deliver on promised EBITDA improvements to reduce leverage and boost earnings. Read the full article on Seeking Alpha分析記事 • Dec 03
Risks To Shareholder Returns Are Elevated At These Prices For Neogen Corporation (NASDAQ:NEOG)
It's not a stretch to say that Neogen Corporation's ( NASDAQ:NEOG ) price-to-sales (or "P/S") ratio of 3.3x right now...分析記事 • Nov 07
Does Neogen (NASDAQ:NEOG) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...株主還元
| NEOG | US Medical Equipment | US 市場 | |
|---|---|---|---|
| 7D | -0.4% | -5.5% | -1.0% |
| 1Y | 114.2% | -19.0% | 14.1% |
業界別リターン: NEOG過去 1 年間で-19 % の収益を上げたUS Medical Equipment業界を上回りました。
リターン対市場: NEOG過去 1 年間で14.1 % の収益を上げたUS市場を上回りました。
価格変動
| NEOG volatility | |
|---|---|
| NEOG Average Weekly Movement | 8.2% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
安定した株価: NEOG 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: NEOGの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1981 | 2,636 | Mike Nassif | www.neogen.com |
ネオジェン・コーポレーションは、米国および海外において、食品および動物の安全に関するさまざまな製品やサービスを開発、製造、販売しています。同社は、「食品安全」および「動物の安全」の2つの事業セグメントを通じて事業を展開しています。 同社は、食品生産者および加工業者向けに、食中毒病原菌、腐敗菌、天然毒素、食品アレルゲン、反芻動物由来副産物、食肉の種別判定、薬物残留、農薬残留、および一般的な衛生上の懸念事項など、ヒト用食品および動物用飼料に含まれる危険物質や意図しない物質を検出するための診断用検査キットおよび関連製品を提供しています。 また、免疫測定法の製造、法医学および動物毒物学、ライフサイエンス研究に使用される試薬や検査キット、 研究用として独自の比色法および化学発光法用基質；「Ideal」および「Prima Tech」ブランドの下で、抗生物質やワクチンの投与に使用される獣医用器具および投与システム；さらに、「Prima Tech」ブランドの下で、農家、牧場主、獣医師向けに、注射、外用・経口投与、人工授精、および動物の識別用に設計された精密機器も提供しています。 さらに、同社は消化補助剤や栄養補助食品、豚・牛・羊のビタミン欠乏症に対処するための「Natural Vitamin E-AD」、 「RenaKare」、Provectaブランドの下で販売されるコンパニオンアニマル用駆虫剤、BotVax B、 「EqStim」；犬の膿皮症の管理を支援する「ImmunoRegulin」；「Provecta」ブランドのコンパニオンアニマル用駆虫薬；「Ramik」、「CyKill」、「Havoc」、「Prozap」、「SureKill」、「StandGuard」ブランドの齧歯類および害虫駆除製品などを提供している。 さらに、獣医用抗生物質「ユニプリム（Uniprim）」の販売、家畜およびコンパニオンアニマル向けのDNAジェノタイピング、シーケンシング、形質分析を提供するsgenomicsラボの運営、ならびに検査担当者が結果を分析・保存し、長期間にわたり複数の拠点から得られた結果の分析を行うことを支援するソフトウェアシステムの提供も行っている。 ネオジェン・コーポレーションは1981年に設立され、ミシガン州ランシングに本社を置いている。
Neogen Corporation 基礎のまとめ
| NEOG 基礎統計学 | |
|---|---|
| 時価総額 | US$2.57b |
| 収益（TTM） | -US$7.90m |
| 売上高(TTM) | US$870.40m |
3.0x
P/Sレシオ-325.2x
PER（株価収益率NEOG は割高か？
公正価値と評価分析を参照収益と収入
| NEOG 損益計算書（TTM） | |
|---|---|
| 収益 | US$870.40m |
| 売上原価 | US$461.90m |
| 売上総利益 | US$408.50m |
| その他の費用 | US$416.40m |
| 収益 | -US$7.90m |
直近の収益報告
May 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.036 |
| グロス・マージン | 46.93% |
| 純利益率 | -0.91% |
| 有利子負債／自己資本比率 | 38.0% |
NEOG の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/11 18:52 |
| 終値 | 2026/09/11 00:00 |
| 収益 | 2026/05/31 |
| 年間収益 | 2026/05/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Neogen Corporation 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。15
| アナリスト | 機関 |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Robert Labick | CJS Securities, Inc. |
| David Westenberg | CL King & Associates, Inc. |